EPR Properties vs Medtronic PLC — how do they compare? EPR Properties trades at $54.74 (market cap $4.17B), while Medtronic PLC trades at $88.07 (market cap $112.24B). The key difference: Medtronic PLC is far larger — about 26.9× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.84%). Which is the better fit depends on your goals — on Pluang, investors hold EPR Properties for 45 Days and Medtronic PLC for 63 Days on average.
| EPR | MDT | |
|---|---|---|
Market Cap | $4.17B | $112.24B |
Volume | 992,716 | 105,663,236 |
Sector | Real Estate | Health |
52-Week High | $64.32 | $105.35 |
52-Week Low | $48.71 | $73.75 |
Typical Hold Time | 45 Days | 63 Days |
Enterprise Value | $7.68B | $131.58B |
Dividend Yield | 6.84% | 3.28% |
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $54.49, up 0.76% today, with a bearish technical signal but oversold oscillators suggesting potential reversal. The REIT shows strong profitability with a 37.66% net income margin and a 6.5% dividend yield, though earnings have been mixed with a recent miss in Q1 2026. Analysts maintain a consensus Buy rating with a $65.50 price target, implying significant upside from current levels.
The outlook is cautiously optimistic given the high dividend yield and discounted valuation, but risks include exposure to interest rate sensitivity and tenant performance in its experiential real estate portfolio. Near-term catalysts include the Q3 2026 earnings release on October 28, 2026, which could validate the company's growth trajectory amid a challenging macro environment.
Medtronic (MDT) trades at $85.51, down 1.81% on the day, with the stock showing bearish technical signals despite strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, maintains a healthy 13.93% net income margin, and offers a solid 3.2% dividend yield with 49 consecutive years of dividend growth. Recent positive developments include FDA clearances for new medical technologies and raised full-year guidance.
MDT presents a compelling value opportunity with analyst consensus pointing to 14% upside to the $97.80 price target. The stock's current valuation multiples (P/E 21.61, P/S 3.01) appear reasonable given the company's stable revenue growth and strong cash flow generation. Key risks include increasing debt levels and competitive pressures in the medical device sector, but the company's dividend aristocrat status and improving operational performance support a positive long-term outlook.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →